Stics and Stones: A Randomised Phase Ii Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (Asa) in Chemoprevention of Ovarian Cancer in Women With Brca1 and Brca2 Mutations

Abstract

Women with a BRCA1 or BRCA2 gene abnormality are at increased risk of ovary and fallopian tube (O&FT) cancers and often have their O&FTs removed to prevent cancer. Microscopic cancers are often seen at the time of surgery. Some studies suggest that aspirin might reduce O&FT cancer risk. This study will assign women to daily aspirin or placebo for 6-24 months before their preventive O&FT surgery. It will provide a better understanding of how O&FT cancers start and the influence aspirin may have.